Taurocholate induces preferential release of phosphatidylcholine from rat liver canalicular vesicles.
OBJECTIVE
Biliary phospholipid secretion involves predominant segregation of canalicular phosphatidylcholine into bile. We tested the hypothesis that micellar concentrations of the major physiologic bile salt taurocholate can preferentially solubilize phosphatidylcholine from the canalicular rat liver plasma membrane.


METHODS
Subcellular fractions from rat liver and kidney were isolated with standardized procedures, incubated in vitro with taurocholate or 3-[(3-cholamidopropyl)dimethylammonio]-propane-1-sulphonate (CHAPS) and released phospholipids determined after centrifugation.


RESULTS
After incubation of canalicular (cLPM) and basolateral (blLPM) rat liver plasma membrane vesicles with 6 and 8 mM taurocholate, the proportion of phosphatidylcholine released was about two-fold higher as compared with its relative contribution to the overall lipid composition of the membranes. Quantitatively, this taurocholate-induced preferential phosphatidylcholine release was about four-fold higher in cLPM (117 nmol) as compared with blLPM (28 nmol). Comparison of membranes from different organs showed that increased sphingomyelin content reduced taurocholate-induced phosphatidylcholine release. Furthermore, phosphatidylcholine release from cLPM did not fit an inverse exponential relationship between membrane sphingomyelin content and phosphatidylcholine release from different starting material, indicating that cLPM is especially prone to taurocholate-induced phosphatidylcholine release. In contrast, in rat liver microsomes and kidney brush border membranes, taurocholate released phospholipids in proportion of their membrane contents, indicating an unspecific membrane solubilizing effect only. Similarly, CHAPS had an unselective lipid solubilizing effects in cLPM and blLPM.


CONCLUSIONS
These results support the concept that the very last step of canalicular phospholipid secretion is mediated in vivo by bile salt-induced vesiculation of phosphatidylcholine-enriched microdomains from the outer leaflet of cLPM.
Gerloff
T
T
Department of Internal Medicine, University Hospital, Zürich, Switzerland.
Meier
P J
PJ
Stieger
B
B
D000818:Animals; D001648:Bile Canaliculi / Q000187:drug effects* / Q000378:metabolism; D002458:Cell Fractionation; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D002756:Cholagogues and Choleretics / Q000494:pharmacology*; D002793:Cholic Acids / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008823:Micelles; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D008871:Microvilli / Q000187:drug effects / Q000378:metabolism; D010713:Phosphatidylcholines / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013109:Sphingomyelins / Q000378:metabolism; D013656:Taurocholic Acid / Q000494:pharmacology*
D002756:Cholagogues and Choleretics; D002793:Cholic Acids; D008823:Micelles; D010713:Phosphatidylcholines; D013109:Sphingomyelins; D013656:Taurocholic Acid; C028213:3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate